Equities Analysts Issue Forecasts for ALDX Q2 Earnings

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) – Equities research analysts at HC Wainwright upped their Q2 2026 earnings per share (EPS) estimates for Aldeyra Therapeutics in a note issued to investors on Monday, May 11th. HC Wainwright analyst M. Caufield now anticipates that the biotechnology company will earn ($0.11) per share for the quarter, up from their previous estimate of ($0.16). HC Wainwright currently has a “Neutral” rating and a $2.00 price objective on the stock. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.44) per share. HC Wainwright also issued estimates for Aldeyra Therapeutics’ Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($0.43) EPS, FY2027 earnings at ($0.22) EPS, FY2028 earnings at ($0.03) EPS and FY2030 earnings at $0.34 EPS.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.07.

Several other analysts also recently issued reports on ALDX. BTIG Research reissued a “buy” rating on shares of Aldeyra Therapeutics in a research note on Tuesday, March 17th. Wall Street Zen downgraded shares of Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $5.50.

Aldeyra Therapeutics Stock Down 2.8%

Shares of NASDAQ:ALDX opened at $1.71 on Wednesday. The company’s fifty day moving average is $2.39 and its two-hundred day moving average is $4.10. Aldeyra Therapeutics has a 12-month low of $1.07 and a 12-month high of $6.18. The company has a market cap of $103.15 million, a P/E ratio of -3.72 and a beta of 1.16.

Hedge Funds Weigh In On Aldeyra Therapeutics

Hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC boosted its holdings in Aldeyra Therapeutics by 456.3% during the first quarter. AQR Capital Management LLC now owns 392,555 shares of the biotechnology company’s stock valued at $2,257,000 after acquiring an additional 321,992 shares during the period. Jacobs Levy Equity Management Inc. bought a new stake in shares of Aldeyra Therapeutics in the first quarter valued at about $218,000. Jane Street Group LLC bought a new stake in shares of Aldeyra Therapeutics in the first quarter valued at about $1,024,000. Acadian Asset Management LLC lifted its stake in Aldeyra Therapeutics by 7,402.7% during the first quarter. Acadian Asset Management LLC now owns 95,960 shares of the biotechnology company’s stock worth $551,000 after purchasing an additional 94,681 shares during the period. Finally, Geode Capital Management LLC lifted its stake in Aldeyra Therapeutics by 0.8% during the second quarter. Geode Capital Management LLC now owns 1,146,597 shares of the biotechnology company’s stock worth $4,392,000 after purchasing an additional 8,769 shares during the period. 59.71% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Aldeyra Therapeutics news, Director Richard Douglas bought 70,000 shares of the stock in a transaction on Thursday, March 19th. The shares were purchased at an average cost of $1.40 per share, with a total value of $98,000.00. Following the completion of the transaction, the director directly owned 195,000 shares of the company’s stock, valued at $273,000. This represents a 56.00% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 8.50% of the stock is owned by insiders.

Aldeyra Therapeutics News Roundup

Here are the key news stories impacting Aldeyra Therapeutics this week:

• Neutral Sentiment: HC Wainwright raised near-term EPS estimates for Q2 2026 and Q3 2026, suggesting slightly better short-term expectations. MarketBeat ALDX page
• Neutral Sentiment: The firm also nudged FY2026 and FY2027 estimates higher and lifted its FY2030 outlook, indicating some longer-term improvement in the model. MarketBeat ALDX page
• Neutral Sentiment: However, HC Wainwright cut its Q4 2026 and FY2028 estimates, and it kept a Neutral rating with a $2.00 price target, which signals limited conviction in near-term upside. MarketBeat ALDX page

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.